Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04946526 · ClinicalTrials.gov registry record · NA
Broccoli Sulforaphane Bioavailability With Mustard
A NA study of Sulforaphane Bioavailability, sponsored by Appalachian State University.
- Completed
- Registry status
- NA
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT04946526: Completed NA study of Sulforaphane Bioavailability, sponsored by Appalachian State University.
NCT04946526 is a NA study of Sulforaphane Bioavailability that has completed, run by Appalachian State University. The registered enrollment target is 16 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04946526, a NA study of Sulforaphane Bioavailability, has completed, sponsored by Appalachian State University.
- COMPLETED
- Registry status
- NA
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
We know that broccoli is a vegetable that is associated with a number of health benefits and is a good choice in a healthy diet. Researchers at major universities, including Johns Hopkins University, have identified nutrients in broccoli that have specific health benefits such as improving antioxidant protection. One of these nutrients is called glucoraphanin (GR). However, in order for GR to deliver health benefits in the human body, it first has to be converted to its active form, sulforaphane (SF). This conversion can happen one of two ways. GR can be converted to SF by our gut bacteria (the microbiota) or it can be converted to SF by an enzyme called myrosinase that is naturally occurring in certain plants, including mustard (the same mustard that is used to make table mustard spread and mayonnaise). The purpose of the present study is to test in healthy human volunteers the oral bioavailability (absorption) of GR in broccoli seed extract (BSE) with or without the presence of active plant myrosinase in mustard seed powder (MSP) delivered in a nutritional supplement.
Primary Outcome
Broccoli glucosinolate metabolite
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Broccoli seed extract
- DIETARY_SUPPLEMENT Broccoli seed extract with mustard seed powder
Study Locations (1)
North Carolina
- Appalachian State University Human Performance Lab, North Carolina Research Campus - Kannapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2022-06-01 |
| Est. Completion | 2022-09-30 |
| Phase | NA |
What the finished NCT04946526 record still lists
NCT04946526 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Sulforaphane Bioavailability appearing as the primary indexed condition, and to 2 interventions - of which Broccoli seed extract is the first listed.
NCT04946526 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT04946526 about?
NCT04946526 is a clinical study titled "Broccoli Sulforaphane Bioavailability With Mustard". We know that broccoli is a vegetable that is associated with a number of health benefits and is a good choice in a healthy diet. Researchers at major universities, including Johns Hopkins University, have identified nutrients in broccoli that have specific health benefits such as improving antioxida...
What is the current status of trial NCT04946526?
This trial is currently completed. It is a NA study. The enrollment target is 16 participants. The study started on 2022-06-01. Estimated completion is 2022-09-30.
What conditions does trial NCT04946526 study?
This clinical trial studies the following conditions: Sulforaphane Bioavailability.
What interventions are being tested in trial NCT04946526?
The interventions under investigation include: Broccoli seed extract (DIETARY_SUPPLEMENT), Broccoli seed extract with mustard seed powder (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04946526?
This trial is sponsored by Appalachian State University, which has 37 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04946526 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04946526's enrollment target sits among peer trials
16 1871st of 2000 higher than 120 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI